EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing antiviral agents against mucormycosis

Ammar A Khan iD, Nour M AlKashef, Mohamed N Seleem iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0342559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Ammar A Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Antiviral Agents, Mucormycosis, Antifungal Agents, Drug Repositioning. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucormycosis is a life-threatening fungal infection with limited treatment options and high mortality rates among immunocompromised individuals. To identify new therapeutic strategies, we screened a library of 618 antiviral compounds against Rhizopus delemar both alone and in combination with amphotericin B (AmB) to search for agents with intrinsic antifungal activity or the ability to enhance AmB’s efficacy. Four candidates, IMB-301, U18666A, BLT-1, and obefazimod, showed potent in vitro effects, with three sustaining growth suppression comparable to AmB for up to 48 h in time-kill assays. The hepatitis C antivirals daclatasvir (DAC) and velpatasvir (VEL) demonstrated strong synergy with AmB across Mucorales isolates, lowering AmB MICs by 4- to 32-fold (ΣFICI < 0.5) and achieving fungistatic suppression of R. delemar at subinhibitory AmB concentrations (0.25 µg/mL). Importantly, neither the standalone antivirals nor their combinations with AmB reduced Vero cell viability at concentrations exceeding 4–16 × their MICs, while selectivity indices ranging from 8 to >32 indicated favorable safety margins. These findings highlight antiviral repurposing as a promising strategy to expand treatment options for mucormycosis and support further translational development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsMucormycosisAntifungal AgentsDrug RepositioningRhizopusAnimalsVero CellsMicrobial Sensitivity TestsChlorocebus aethiopsAmphotericin BValineHumansImidazolesDrug SynergismPyrrolidinesCarbamates

Substanzen

Antiviral AgentsAntifungal AgentsAmphotericin BValineImidazolesPyrrolidinesCarbamates

Autor:innen und Institutionen

  • Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
  • Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.

ORCID-Profile: Ammar A Khan, Mohamed N Seleem

Förderung

  • Foundation for the National Institutes of Health

Zitieren

APA

Khan, A. A., AlKashef, N. M., & Seleem, M. N. (2026). Repurposing antiviral agents against mucormycosis. PLOS One. https://doi.org/10.1371/journal.pone.0342559

Vancouver

Khan AA, AlKashef NM, Seleem MN. Repurposing antiviral agents against mucormycosis. PLOS One. 2026. doi:10.1371/journal.pone.0342559

BibTeX
@article{Khan2026,
  author = {Khan, Ammar A and AlKashef, Nour M and Seleem, Mohamed N},
  title = {Repurposing antiviral agents against mucormycosis},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342559}
}
Kostenlos starten →